Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2018

View Archived Issues

Prothena reorganizing resources to advance neuroscience pipeline

Researchers present novel bifunctional mu-receptor agonist and NPFF receptor antagonist, KGFF-09

Novel experimental model of ZIKV infection with pregnant common marmoset presented

Mouse model of VIPR2 gene copy number variation gives insight into neuropsychiatric disorders

Researchers present new antiviral compounds

EMA accepts European filing for edaravone for ALS

New IDO-1 inhibitor PX-D26116 has improved metabolic stability compared to epacadostat

Actavalon patents AhR agonists for cancer

Wuhan Bowo Biological Technology divulges new influenza and RSV vaccines

Centogene collaborates with Aldeyra Therapeutics in Sjogren-Larsson syndrome

AB Science offers update on European MAA for masitinib in ALS

JCR obtains approval in Brazil to begin phase II trial of JR-141 for Hunter's syndrome

ImmuPharma releases further data analysis from pivotal trial of Lupuzor in SLE

FDA grants orphan drug designation to SNX-5422 for neuroendocrine tumors

Tazemetostat granted U.S. orphan drug designation for chordoma

Arroyo BioSciences' AB-22 granted U.S. orphan drug designation for IPF

FDA approves Cimzia for the treatment of adults with moderate to severe plaque psoriasis

IDMC recommends continuation of phase III study of Zepsyre in small cell lung cancer

FDA grants priority review for gilteritinib NDA in relapsed or refractory AML

REXGEX trial shows importance of immune status for enhanced efficacy with CetuGEX

Chugai seeks Japanese approval for Actemra for cytokine release syndrome

Japanese approval sought for Trelegy Ellipta

Kowa to launch Parmodia in Japan for hyperlipidemia

Researchers discover new targets for lymphoblastic leukemia immunotherapy

Pfizer seeks Japanese approval of dacomitinib for EGFR mutation-positive NSCLC

Phase III IMpower130 study of Tecentriq in NSCLC meets coprimary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...